Dr. DeNittis named to NCI Rectal-Anal Task Force



By Paul Gilman, MD, Director, Clinical Research Center, LIMR


Albert DeNittis, MD, Principal Investigator of the Main Line NCORP and Radiation Oncologist at Lankenau Medical Center, has been awarded one of 16 positions within the National Cancer Institute’s Steering Committees and Task Force program.


Representing the Main Line NCORP Program, Dr. DeNittis will serve a three-year term starting October 1, 2017 on the Rectal-Anal Task Force.  In this role, Dr. DeNittis will provide input so the phase III and large phase II clinical trial concepts that are developed and approved for NCI support are feasible and meet the needs of surgical, medical and radiation oncologists and their patients.


He will work to set new standards in cancer care for cancers of the rectum and anus.  He will try to integrate new translational and clinical research in Bethesda at the National Cancer Institute and bring cutting edge treatment to the institutions and patients of our country.


Main Line NCORP is one of only 34 community programs in the country.  Dr DeNittis is the Principal Investigator, supported by 30+ sub-investigators (a mix of medical, radiation and surgical oncology) along with clinical research nurses and coordinators across Lankenau Medical Center, Bryn Mawr, Paoli and Riddle Hospitals.  Main Line Health currently offers over 60 cancer clinical trials across a variety of cancer types to patients within the system.  Real-time trial information is available at:  http://www.limr.org/ncorp.


This entry was posted in Clinician News and tagged , , . Bookmark the permalink.

Leave a Reply

Your email address will not be published.